Use of Noninsulin Antidiabetic Meds Increasing for T2D in Pregnancy
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Dec. 13, 2023 -- Use of second-line noninsulin antidiabetic medications (ADMs) is increasing for type 2 diabetes (T2D) in pregnancy, but use is not associated with a significantly increased risk for major congenital malformations (MCMs), according to a study published online Dec. 11 in JAMA Internal Medicine.
Carolyn E. Cesta, Ph.D., from the Karolinska Institute in Stockholm, and colleagues conducted an observational population-based cohort study using data from four Nordic countries, the U.S. MarketScan Database, and the Israeli Maccabi Health Services database. The relative risks for MCMs in infants were compared for periconceptional exposure to sulfonylureas, dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, and sodium-glucose cotransporter 2 (SGLT2) inhibitors versus insulin (active comparator).
Differences were observed in periconceptional exposure to second-line noninsulin ADMs between the countries (32, 295, and 73 per 100,000 pregnancies in the Nordics, United States, and Israel, respectively), which increased during the study, especially in the United States. The researchers found that the standardized prevalence of MCMs was 3.7 and 5.3 percent in all infants and in infants born to women with T2D, respectively. Prevalence was 9.7, 6.1, 8.3, 7.0, and 7.8 percent for infants exposed to sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and insulin, respectively. The adjusted relative risks were not significant for infants exposed to sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors compared with insulin.
"Our findings provide initial reassurance of safety for infants prenatally exposed to these medications," Cesta said in a statement.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
AI-Informed Health App Aids Diabetes Outcomes
WEDNSDAY, May 15, 2024 -- Use of an artificial intelligence (AI)-informed health app aids diabetes outcomes and cuts atherosclerotic cardiovascular disease (ASCVD) risk, according...
Four in 10 Adults With Diabetes Report Taking a GLP-1 Receptor Agonist
TUESDAY, May 14, 2024 -- One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent say they are currently using...
Fat-Enlarged Axillary Nodes on Mammogram May Indicate Higher CVD Risk
TUESDAY, May 14, 2024 -- Fat-enlarged axillary nodes on screening mammograms can predict the risk for cardiovascular disease (CVD), according to a study presented at the annual...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.